Meletios Athanasios Dimopoulos
National and Kapodistrian University of Athens
H-index: 164
Europe-Greece
Top articles of Meletios Athanasios Dimopoulos
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA | American Journal of Hematology | Evangelos Terpos Ioannis Ntanasis‐Stathopoulos Maria Gavriatopoulou Eirini Katodritou Evdoxia Hatjiharissi | 2024/1/31 |
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment | Clinical Lymphoma Myeloma and Leukemia | Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon | 2024/3/1 |
Latest Research | Scientific Advisory Panel | ||
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf)+ bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd … | Maria-Victoria Mateos Pawel Robak Marek Hus Zhongjun Xia Vera Zherebtsova | 2024/2/6 | |
Genetic justification of COVID‐19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithm | Journal of Cellular and Molecular Medicine | Panagiotis G Asteris Amir H Gandomi Danial J Armaghani Markos Z Tsoukalas Eleni Gavriilaki | 2024/2 |
Chemotherapy response score as a predictor of survival in ovarian cancer patients | European Journal of Obstetrics & Gynecology and Reproductive Biology | Ioannis Rodolakis Michalis Liontos Vasilios Pergialiotis Dimitrios Haidopoulos Maria Kaparelou | 2024/5/1 |
Single‐cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patients | HemaSphere | Tina Bagratuni Foteini Aktypi Ourania Theologi Maria Sakkou Kleio Maria Verrou | 2024/2 |
EPH/Ephrin Signaling in Normal Hematopoiesis and Hematologic Malignancies: Deciphering Their Intricate Role and Unraveling Possible New Therapeutic Targets | Ioanna E Stergiou Stavros P Papadakos Anna Karyda Ourania E Tsitsilonis Meletios-Athanasios Dimopoulos | 2023/8/4 | |
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended … | The Lancet Haematology | Meletios A Dimopoulos Evangelos Terpos Mario Boccadoro Sosana Delimpasi Meral Beksac | 2023/10/1 |
MM-509 A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose … | Clinical Lymphoma Myeloma and Leukemia | Katja Weisel Vania TM Hungria Atanas Radinoff Sosana Delimpasi Mikala Gabor | 2023/9/1 |
Effects of treatment response on echocardiographic features among patients with light-chain cardiac amyloidosis | European Heart Journal | A Briasoulis A Rempakos I Petropoulos D Bampatsias F Theodorakakou | 2023/11 |
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study | Clinical Lymphoma Myeloma and Leukemia | Sundar Jagannath Sosana Delimpasi Sebastian Grosicki Dane R Van Domelen Ohad S Bentur | 2023/12/1 |
Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and … | Blood | Francesca Gay Wilfried Roeloffzen Meletios A Dimopoulos Laura Rosiñol Marjolein van der Klift | 2023/11/28 |
A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed … | Blood | Evangelos Terpos Efstathios Kastritis Argiris Symeonidis Anastasia Pouli Sosana Delimpasi | 2023/11/28 |
Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network | Blood | Efstathios Kastritis Monique C Minnema Meletios A Dimopoulos Giampaolo Merlini Foteini Theodorakakou | 2023/11/28 |
OA-44 Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a … | Clinical Lymphoma Myeloma and Leukemia | Meral Beksac Paul Richardson Albert Oriol Jindriska Lindsay Fredrik Schjesvold | 2023/9/1 |
Phase 3 randomized study of daratumumab (DARA)+ bortezomib, lenalidomide, and dexamethasone (VRd) versus Vrd alone in patients (pts) with newly diagnosed multiple myeloma (NDMM … | Blood | Pieter Sonneveld Meletios A Dimopoulos Mario Boccadoro Hang Quach P Joy Ho | 2023/11/21 |
P-046 Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple … | Clinical Lymphoma Myeloma and Leukemia | Paula Rodriguez-Otero Nisha Joseph Shaji Kumar Xavier Leleu Salomon Manier | 2023/9/1 |
P-033 Real world evaluation of teclistamab in patients with RRMM: results from the IMF immunotherapy database project | Clinical Lymphoma Myeloma and Leukemia | Yi Lin Sireesha Asoori Maringanti Efstathios Kastritis Joaquín Martinez-Lopez Larissa Argenau Marques Brunaldi | 2023/9/1 |
P-167 Serum BCMA levels evaluated by Elecsys sBCMA assay at diagnosis have prognostic value in patients with multiple myeloma | Clinical Lymphoma Myeloma and Leukemia | Evangelos Terpos Ioannis Ntanasis-Stathopoulos Panagiotis Malandrakis Aliya Sarmanova Despina Fotiou | 2023/9/1 |
Co-Authors
